Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D)
Heart failure | |
ICD-10 | I50.0 |
---|---|
ICD-9 | 428.0 |
DiseasesDB | 16209 |
MedlinePlus | 000158 |
MeSH | D006333 |
Congestive Heart Failure Microchapters |
Pathophysiology |
---|
Differentiating Congestive heart failure from other Diseases |
Diagnosis |
Treatment |
Medical Therapy: |
Surgical Therapy: |
ACC/AHA Guideline Recommendations
|
Specific Groups: |
Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D) On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]
Overview
ACC/AHA Guidelines- Treatment of Patients with Refractory End-Stage Heart Failure (Stage D) (DO NOT EDIT) [1][2]
“ |
Class I1. Meticulous identification and control of fluid retention is recommended in patients with refractory endstage HF. [3][4][5][6][7][8][9][10] (Level of Evidence: B) 2. Referral for cardiac transplantation in potentially eligible patients is recommended for patients with refractory end-stage HF. [11] (Level of Evidence: B) 3. Referral of patients with refractory end-stage HF to an HF program with expertise in the management of refractory HF is useful. [12][13][14][15] (Level of Evidence: A) 4. Options for end-of-life care should be discussed with the patient and family when severe symptoms in patients with refractory end-stage HF persist despite application of all recommended therapies. (Level of Evidence: C) 5. Patients with refractory end-stage HF and implantable defibrillators should receive information about the option to inactivate defibrillation. (Level of Evidence: C) Class IIa1. Consideration of an LV assist device as permanent or “destination” therapy is reasonable in highly selected patients with refractory end-stage HF and an estimated 1-year mortality over 50% with medical therapy. (222,223) (Level of Evidence: B) Class IIb1. Pulmonary artery catheter placement may be reasonable to guide therapy in patients with refractory end-stage HF and persistently severe symptoms. (217,224) (Level of Evidence: C) 2. The effectiveness of mitral valve repair or replacement is not established for severe secondary mitral regurgitation in refractory end-stage HF. (225-227) (Level of Evidence: C) 3. Continuous intravenous infusion of a positive inotropic agent may be considered for palliation of symptoms in patients with refractory end-stage HF. (228,229) (Level of Evidence: C) Class III1. Partial left ventriculectomy is not recommended in patients with non ischemic cardiomyopathy and refractory end-stage HF. (Level of Evidence: C) 2. Routine intermittent infusions of vasoactive and positive inotropic agents are not recommended for patients with refractory end-stage HF. (230,231) [16][17] (Level of Evidence: A) |
” |
Vote on and Suggest Revisions to the Current Guidelines
Guidelines Resources
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
- 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [2]
References
- ↑ 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (12):e154-235. DOI:10.1161/CIRCULATIONAHA.105.167586 PMID: 16160202
- ↑ 2.0 2.1 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967
- ↑ Brater DC, Chennavasin P, Seiwell R (1980). "Furosemide in patients with heart failure: shift in dose-response curves". Clinical Pharmacology and Therapeutics. 28 (2): 182–6. PMID 7398185. Unknown parameter
|month=
ignored (help);|access-date=
requires|url=
(help) - ↑ Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P (1996). "Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion". Journal of the American College of Cardiology. 28 (2): 376–82. doi:10.1016/0735-1097(96)00161-1. PMID 8800113. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Cotter G, Weissgarten J, Metzkor E, Moshkovitz Y, Litinski I, Tavori U, Perry C, Zaidenstein R, Golik A (1997). "Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure". Clinical Pharmacology and Therapeutics. 62 (2): 187–93. doi:10.1016/S0009-9236(97)90067-9. PMID 9284855. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ (2006). "Diuretics for heart failure". Cochrane Database of Systematic Reviews (Online) (1): CD003838. doi:10.1002/14651858.CD003838.pub2. PMID 16437464. Retrieved 2012-04-06.
- ↑ Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P (2005). "Early ultrafiltration in patients with decompensated heart failure and diuretic resistance". Journal of the American College of Cardiology. 46 (11): 2047–51. doi:10.1016/j.jacc.2005.05.099. PMID 16325040. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E (2003). "Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)". Journal of the American College of Cardiology. 42 (4): 705–8. PMID 12932605. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P (2002). "Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure". Journal of the American College of Cardiology. 40 (2): 304–10. PMID 12106936. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A (2002). "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials". International Journal of Cardiology. 82 (2): 149–58. PMID 11853901. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Jessup M, Banner N, Brozena S, Campana C, Costard-Jäckle A, Dengler T, Hunt S, Metra M, Rahmel A, Renlund D, Ross H, Warner Stevenson L (2006). "Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006". The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation. 25 (9): 1003–23. doi:10.1016/j.healun.2006.06.007. PMID 16962463. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ McAlister FA, Lawson FM, Teo KK, Armstrong PW (2001). "A systematic review of randomized trials of disease management programs in heart failure". The American Journal of Medicine. 110 (5): 378–84. PMID 11286953. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Whellan DJ, Hasselblad V, Peterson E, O'Connor CM, Schulman KA (2005). "Metaanalysis and review of heart failure disease management randomized controlled clinical trials". American Heart Journal. 149 (4): 722–9. doi:10.1016/j.ahj.2004.09.023. PMID 15990759. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R (2007). "The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design". American Heart Journal. 153 (4): 478–84. doi:10.1016/j.ahj.2007.02.004. PMID 17383282. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Clark RA, Inglis SC, McAlister FA, Cleland JG, Stewart S (2007). "Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis". BMJ (Clinical Research Ed.). 334 (7600): 942. doi:10.1136/bmj.39156.536968.55. PMC 1865411. PMID 17426062. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N et al. (1986) Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 112 (4):787-91. PMID: 3766379
- ↑ Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E et al. (1999) Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 138 (2 Pt 1):247-53. PMID: 10426835